Widely prescribed pain killers that provide relief with minimal side effects may have more pain-relieving properties than previously identified. A new study funded by the National Institute of Neurological Disorders and Stroke shows that non-steroidal anti-inflammatory drugs not only relieve pain at the local site of inflammation, but in fact affect the entire central nervous system.
Widely prescribed pain killers that provide relief with minimal side effects may have more pain-relieving properties than previously identified. A new study funded by the National Institute of Neurological Disorders and Stroke shows that non-steroidal anti-inflammatory drugs not only relieve pain at the local site of inflammation, but in fact affect the entire central nervous system.
NSAIDs reduce sensitivity of nerves in the central nervous system by inhibiting production of the COX-2 enzyme responsible for pain and inflammation.
A research team led by Clifford J. Woolf at Massachusetts General Hospital in Boston used an animal model to study COX-2's role in inflammatory pain. When inflammation occurred, researchers found COX-2 throughout the central nervous system, as well as at the local site of inflammation. They also found that inhibiting COX-2 production within the spinal cord and brain decreased pain and reduced hypersensitivity to normal sensations such as touch. Researchers now believe the widespread distribution of COX-2 within the central nervous system may contribute to the muscle and joint pain, depression, lethargy and loss of appetite that often occur with inflammation and infection.
"The findings indicate new treatment options for arthritis and other inflammatory pain conditions," said Cheryl A. Kitt, program director for pain research at the NINDS. "Targeting the central nervous system when using NSAIDs, rather than the specific peripheral pain site, may result in more effective pain relief." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.